50
Participants
Start Date
April 30, 2011
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Olopatadine hydrochloride ophthalmic solution, 0.7%
Treatment A
Olopatadine hydrochloride ophthalmic solution vehicle
Treatment B, inactive ingredients used as placebo
Ketotifen fumarate ophthalmic solution, 0.025%
Treatment C
Lead Sponsor
Alcon Research
INDUSTRY